John A. Kosteva

John A. Kosteva, MD, serves as Clinical Associate Professor of Medicine (Hematology-Oncology) at the University of Pennsylvania, practicing at Abramson Cancer Center Valley Forge with hospital privileges at the Hospital of the University of Pennsylvania. Specializing in lung cancer treatment for patients aged 18+, he maintains a 4.9/5 patient satisfaction rating from 882 reviews, noted for his expertise in explaining complex imaging results and molecular testing.

His medical training includes:

• Medical School: Temple University School of Medicine
• Residency: Temple University Hospital
• Fellowship: Fox Chase Cancer Center
• Fellowship: Temple University Hospital

Dr. Kosteva's research centers on advancing precision oncology for non-small cell lung cancer (NSCLC), with dual focus on molecular genotyping implementation and skeletal metastasis management. His work bridges genomic discovery with clinical practice through electronic medical record interventions and real-world treatment outcome analyses, emphasizing biomarker-driven therapeutic strategies and immunotherapy optimization.

Analysis of his 2016-2024 publications reveals evolving expertise from foundational skeletal metastasis management (2008) to contemporary molecular genotyping interventions (2024). Current work emphasizes overcoming systemic barriers to precision medicine, with significant contributions to understanding KRAS-mutated NSCLC outcomes and checkpoint inhibitor consolidation therapy implementation in academic health systems.

As a Clinical Associate Professor, Dr. Kosteva contributes to medical education while maintaining active clinical practice. His research collaborations span Penn Medicine's oncology divisions, radiation oncology, and translational science teams, focusing on improving NSCLC treatment accessibility and efficacy through both clinical trials and health services research.